 |
|
Medical Technology News
PRESS RELEASE ARCHIVES FROM SEND2PRESS® NEWSWIRE
NOTICE: THIS IS ARCHIVAL CONTENT AND LIKELY OUT OF DATE.
Edited for Send2Press by Carly Zander
Dr. Herbert A. Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at M.D. Anderson Cancer Center accepts position as Chairman of the Scientific Advisory Board of Health Discovery Corporation
WACO, Texas - Jan. 27, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC
Bulletin Board: HDVY), a systems biology oriented biomarker and pathway discovery company,
which uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling
(FGM) techniques, to help identify and characterize diagnostic targets and therapeutic drug
candidates from complex genomic, proteomic and clinical data sets, is honored that Dr.
Herbert Fritsche of M.D. Anderson Cancer Center has accepted the position as Chairman of the
Company's Scientific Advisory Board joining other distinguished members including Dr. Kary
Mullis, recipient of the Nobel Prize for his invention of PCR.
Dr. Herbert A. Fritsche is Professor of Laboratory Medicine and Chief of the Clinical
Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas.
During his 35 years at M.D. Anderson Cancer Center, Dr. Fritsche has focused his research
activities on the development and validation of cancer diagnostics. Dr. Fritsche has
participated in the validation and FDA clearance process for every commercial serum tumor
marker product currently in use in the United States.
Dr. Fritsche has served as President of the Clinical Ligand Assay Society (CLAS) and on
various committees for both the CLAS and the American Association for Clinical Chemistry
(AACC). He is a fellow of the National Academy of Clinical Biochemistry and was awarded the
National Award for Contributions in Education by the AACC; the Outstanding Clinical Chemist
Award by the Texas Section, AACC; a Dean's Excellence Award for the University of Texas
Graduate School of Biomedical Science; a Distinguished Scientist Award from the CLAS; and
the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical
Biochemistry from the National Academy of Clinical Biochemistry.
Dr. Fritsche currently serves on the Expert Panel for developing Tumor Marker Practice
Guidelines for the American Society of Clinical Oncology, and the Laboratory Practice
Guidelines Committee for the National Academy of Clinical Biochemistry. In addition, he
serves on the Editorial Board of six international scientific journals.
Dr. Fritsche serves as a consultant/advisor to the National Cancer Institute and for some
major international diagnostic companies and biotech start-up companies. Dr. Fritsche has
published over 170 peered reviewed scientific papers, invited articles and book chapters.
Dr. Fritsche holds 3 patents and has 2 other applications on file. He has lectured
extensively for many years at international and national meetings.
"We are extremely honored that Dr. Herbert Fritsche, one of the worlds leading experts on
tumor biomarkers, with his vast and unique experience has agreed to become Chairman of our
Scientific Advisory Board," said Stephen D. Barnhill, M.D., Chairman and CEO of Health
Discovery Corporation. "In addition to providing unparalleled scientific expertise, Dr.
Fritsche will bring significant commercialization experience having participated in the
validation and FDA clearance process for every commercial serum tumor marker product
currently in use in the United States."
Dr. Fritsche commented, "I believe that the systems biology approach to biomarker and
pathway discovery will provide the diagnostic and drug targets that will advance patient
care to the point where personalized medicine will become a reality." Dr. Fritsche continued
"I look forward to working with Dr. Barnhill and the distinguished group of experts he has
assembled to achieve the goal of advancing scientific discovery and commercializing the next
generation of diagnostic markers and drug targets." For more information contact Robert S.
Braswell IV of Health Discovery Corporation +1-866-953-9031 or Info@dwcell.com.
• Previous News from Health Discovery Corporation
Jan. 26, 2004
Health Discovery Corporation Announces Agreement With M.D. Anderson Cancer Center for Biomarker and Pathway Discovery in Prostate Cancer
Jan. 8, 2004
Health Discovery Corporation Releases Shareholder Letter
Jan. 2, 2004
Health Discovery Corporation Completes the Acquisition of Fractal Genomics
Nov. 25, 2003
Dr. Tin-Chuen Yeung Named To Health Discovery Corporation Scientific Advisory Board
Nov. 14, 2003
Health Discovery Corporation, Inc. Announces the Appointment of Joe Fanelli to the Management Team as Director of Corporate Development
Nov. 6, 2003
Dr. Bernhard Scholkopf, Max Plank Director, Named To Health Discovery Corporation Scientific Advisory Board
Nov. 6, 2003
Direct Wireless Communications Inc. Announces Name Change To Health Discovery Corporation
Nov. 3, 2003
Direct Wireless Communications, Inc. Announces The Appointment Of David Cooper, M.D., Ph.D. To The Board Of Directors And The Management Team
Oct. 31, 2003
Direct Wireless Communications, Inc. Announces Agreement With Md Anderson Cancer Center For Cancer Discovery
Oct. 27, 2003
Direct Wireless Communications, Inc. Announces Board And Management Changes
Oct. 2, 2003
Ramananda K. Madyastha, M.D., Ph.D., Award Winning Cancer Researcher Named To Direct Wireless Communications Scientific Advisory Board
Oct. 2, 2003
Ramananda K. Madyastha, M.D., Ph.D., Award Winning Cancer Researcher Named To Direct Wireless Communications Scientific Advisory Board
Sept. 25, 2003
Direct Wireless Completes Acquisition Of The Barnhill Group
Sept. 18, 2003
Direct Wireless Communications Hosts Reception For 15th Annual Genomic Sequencing And Analysis Conference Held By The Institute For Genomic Research (Tigr) In Savannah, Georgia
Sept. 9, 2003
Dr. Kary Mullis, Nobel Prize Winning Chemist Named To Direct Wireless Communications Scientific Advisory Board
Sept. 3, 2003
Dr. Herbert Fritsche Presents Cancer Discovery At International Cancer Meeting
Sept. 2, 2003
Direct Wireless Enters Into A Letter Of Agreement To Acquire Fractal Genomics
August 26, 2003
Direct Wireless Enters Into A Letter Of Agreement To Acquire The Barnhill Group
FOR INFORMATION ABOUT THE COMPANY OR ORGANIZATION(S) MENTIONED IN THE ABOVE BUSINESS NEWS ARTICLE, PLEASE CONTACT THE COMPANY DIRECTLY AND NOT THIS WEBSITE.
DISCLAIMER: the above business news article is believed accurate but not guaranteed, and is based on business news supplied by the company or organization mentioned and/or quoted in the story. Financial/Stock news may contain forward looking statements and public companies should be thoroughly researched before considering material investment. Neotrope/Send2Press makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news item are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope/Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article.
USE OF THE ABOVE NEWS ARTICLE
Article is Copr. © 2004 Neotrope/Send2Press. Reproduction of this news article in any form requires written authorization. You may freely link to this article. For more information on using this article in print or on your website, please visit:
www.freeNewsArticles.com™.
|
|
|
|
Add Our News Headlines to Your Website Free
Free headline feed
Journalists & Editors
Choose your news by
preferred topic(s).
Privacy protected.
MORE INFO
Archived Releases
Most Recent Releases
NOTICE: THIS PAGE IS ARCHIVAL CONTENT AND SHOULD NOT BE RELIED UPON FOR ACCURACY.
|
|
|
